TGFB1 and allergic asthma: Mitochondrial-targeted antioxidant therapy abrogates AHR, inflammation, TGF-β-mediated collagen deposition, decreases ROS production, and downregulates NF-κB activity in allergic asthma (Jaffer et al., 2015; Sebag et al., 2017).